GlobalData’s new report, “Europe In Vitro Diagnostics Market Outlook to 2017- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture” provides key market data on the Europe In Vitro Diagnostics market – France, Germany, Italy, Spain and United Kingdom. The report provides value (USD million) data for all the market categories – Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants.
Europe In Vitro Diagnostics Market Outlook to 2017
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
Scope
- Countries covered include France, Germany, Italy, Spain and United Kingdom.
- Market size and company share data for In Vitro Diagnostics market categories – Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture.
- Annualized market revenues (USD million) data for each of the market categories in each of the country. Data from 2003 to 2010, forecast forward for 7 years to 2017.
- 2010 company shares and distribution shares data for each of the market categories and countries.
- Global corporate-level profiles of key companies operating within the Europe In Vitro Diagnostics market.
- Key players covered include F. Hoffmann-La Roche Ltd., Siemens Healthcare, Abbott Laboratories, Beckman Coulter, Inc., bioMerieux S.A., Ortho-Clinical Diagnostics Inc. and others.
Reasons to buy
- Develop business strategies by identifying the key market categories and segments poised for strong growth.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the Europe In Vitro Diagnostics competitive landscape.
- Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.
- What are the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.
Table of Contents
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 12
2 Introduction 14
2.1 What is This Report About? 14
3 In Vitro Diagnostics in Europe 15
3.1 In Vitro Diagnostics Cross Country Comparison, USD Actual, 2003-2017 15
3.2 In Vitro Diagnostics, Europe, Overall Revenue ($m), USD Actual, 2003-2017 16
3.3 In Vitro Diagnostics, Europe, Company share (2009-2010) 24
4 In Vitro Diagnostics In Germany 26
4.1 In Vitro Diagnostics, Germany, Overall Revenue ($m), USD Actual, 2003-2017 26
4.2 In Vitro Diagnostics, Germany, Distribution Share (2009-2010) 32
4.3 In Vitro Diagnostics, Germany, Company share (2009-2010) 36
5 In Vitro Diagnostics In France 52
5.1 In Vitro Diagnostics, France, Overall Revenue ($m), USD Actual, 2003-2017 52
5.2 In Vitro Diagnostics, France, Distribution Share (2009-2010) 58
5.3 In Vitro Diagnostics, France, Company share (2009-2010) 62
6 In Vitro Diagnostics In Italy 78
6.1 In Vitro Diagnostics, Italy, Overall Revenue ($m), USD Actual, 2003-2017 78
6.2 In Vitro Diagnostics, Italy, Distribution Share (2009-2010) 84
6.3 In Vitro Diagnostics, Italy, Company share (2009-2010) 88
7 In Vitro Diagnostics In United Kingdom 104
7.1 In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Actual, 2003-2017 104
7.2 In Vitro Diagnostics, United Kingdom, Distribution Share (2009-2010) 110
7.3 In Vitro Diagnostics, United Kingdom, Company share (2009-2010) 114
8 In Vitro Diagnostics In Spain 130
8.1 In Vitro Diagnostics, Spain, Overall Revenue ($m), USD Actual, 2003-2017 130
8.2 In Vitro Diagnostics, Spain, Distribution Share (2009-2010) 136
8.3 In Vitro Diagnostics, Spain, Company Share (2009-2010) 140
9 Overview of Key Companies in Europe In Vitro Diagnostics Market 156
9.1 F. Hoffmann-La Roche Ltd. 156
9.2 Siemens Healthcare 157
9.3 Abbott Laboratories 158
9.4 Beckman Coulter, Inc. 159
9.5 bioMerieux S.A. 160
9.6 Ortho-Clinical Diagnostics Inc. 161
9.7 Sysmex Corporation 162
9.8 Bio-Rad Laboratories, Inc. 162
9.9 Becton, Dickinson and Company 162
9.10 DiaSorin S.p.A 163
9.11 Phadia AB 163
9.12 Alere Inc. 163
9.13 DIAGNOSTICA STAGO, Inc. 164
9.14 Qiagen N.V. 164
9.15 Gen-Probe Incorporated 164
9.16 HORIBA, Ltd. 165
9.17 Thermo Fisher Scientific Inc. 165
9.18 Grifols, S.A. 165
9.19 PerkinElmer, Inc. 166
9.20 Danaher Corporation 166
9.21 The Elitech Group 166
9.22 BioSystems International 167
9.23 Life Technologies Corporation 167
9.24 Immucor, Inc. 167
9.25 Hologic, Inc. 168
9.26 Cellestis Limited 168
9.27 Atlas Medical 168
10 In Vitro Diagnostics Market Pipeline Products 169
10.1 Clinical Chemisty Market Pipeline Products 169
10.2 Immuno Chemistry Market Pipeline Products 172
10.3 Haematology Market Pipeline Products 175
10.4 Infectious Immunology Market Pipeline Products 177
10.5 Microbiology Culture Market Pipeline Products 181
10.6 Histology and Cytology Market Pipeline Products 182
10.7 Genetic Testing Market Pipeline Products 183
11 Financial Deals Landscape 188
11.1 Merger 188
11.2 Acquisition 189
11.3 Partnerships 220
12 Recent Developments 291
12.1 Strategy And Business Planning 291
12.2 Legal and Regulatory 308
12.3 Government and Public Interest 313
12.4 Product News 329
13 Appendix 364
13.1 Definitions of Markets Covered in the Report 365
13.2 Research Methodology 367
13.3 Secondary Research 367
13.4 Primary Research 368
13.5 Models 368
13.6 Forecasts 369
13.7 Expert Panels 369
13.8 GlobalData Consulting 369
13.9 Currency Conversion 370
13.10 Contact Us 370
13.11 Disclaimer 370
List of Tables
Table 1:In Vitro Diagnostics, Cross Country Comparison, USD Actual, 2003-2017 25
Table 2:In Vitro Diagnostics, Europe, Overall Revenue ($m), USD Actual, 2003-2017 27
Table 3:In Vitro Diagnostics, Europe, Cross-Category Analysis, 2003-2017 29
Table 4:In Vitro Diagnostics, Europe, Overall Revenue ($m), USD Actual, Historic, 2003-2010 31
Table 5:In Vitro Diagnostics, Europe, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 33
Table 6:In Vitro Diagnostics, Europe, Company Share by Revenue ($m), USD Actual, 2009-2010 35
Table 7:In Vitro Diagnostics, Germany, Overall Revenue ($m), USD Actual, 2003-2017 37
Table 8:In Vitro Diagnostics, Germany, Overall Revenue ($m), USD Actual, Historic, 2003-2010 39
Table 9:In Vitro Diagnostics, Germany, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 41
Table 10:Clinical Chemistry, Germany, Distribution Share by Revenue ($m), USD Actual, 2009-2010 42
Table 11:Genetic Testing, Germany, Distribution Share by Revenue ($m), USD Actual, 2009-2010 42
Table 12:Haematology, Germany, Distribution Share by Revenue ($m), USD Actual, 2009-2010 43
Table 13:Histology And Cytology, Germany, Distribution Share by Revenue ($m), USD Actual, 2009-2010 43
Table 14:Immuno Chemistry, Germany, Distribution Share by Revenue ($m), USD Actual, 2009-2010 44
Table 15:Infectious Immunology, Germany, Distribution Share by Revenue ($m), USD Actual, 2009-2010 44
Table 16:Microbiology Culture, Germany, Distribution Share by Revenue ($m), USD Actual, 2009-2010 45
Table 17:In Vitro Diagnostics, Germany, Company share by Revenue ($m), USD Actual, 2009-2010 47
Table 18:Clinical Chemistry, Germany, Company share by Revenue ($m), USD Actual 2009-2010 49
Table 19:Genetic Testing, Germany, Company share by Revenue ($m), USD Actual 2009-2010 51
Table 20:Haematology, Germany, Company share by Revenue ($m), USD Actual 2009-2010 53
Table 21:Histology And Cytology, Germany, Company share by Revenue ($m), USD Actual 2009-2010 55
Table 22:Immuno Chemistry, Germany, Company share by Revenue ($m), USD Actual 2009-2010 57
Table 23:Infectious Immunology, Germany, Company share by Revenue ($m), USD Actual 2009-2010 59
Table 24:Microbiology Culture, Germany, Company share by Revenue ($m), USD Actual 2009-2010 61
Table 25:In Vitro Diagnostics, France, Overall Revenue ($m), USD Actual, 2003-2017 63
Table 26:In Vitro Diagnostics, France, Overall Revenue ($m), USD Actual, Historic, 2003-2010 65
Table 27:In Vitro Diagnostics, France, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 67
Table 28:Clinical Chemistry, France, Distribution Share by Revenue ($m), USD Actual, 2009-2010 68
Table 29:Genetic Testing, France, Distribution Share by Revenue ($m), USD Actual, 2009-2010 68
Table 30:Haematology, France, Distribution Share by Revenue ($m), USD Actual, 2009-2010 69
Table 31:Histology And Cytology, France, Distribution Share by Revenue ($m), USD Actual, 2009-2010 69
Table 32:Immuno Chemistry, France, Distribution Share by Revenue ($m), USD Actual, 2009-2010 70
Table 33:Infectious Immunology, France, Distribution Share by Revenue ($m), USD Actual, 2009-2010 70
Table 34:Microbiology Culture, France, Distribution Share by Revenue ($m), USD Actual, 2009-2010 71
Table 35:In Vitro Diagnostics, France, Company share by Revenue ($m), USD Actual, 2009-2010 73
Table 36:Clinical Chemistry, France, Company share by Revenue ($m), USD Actual 2009-2010 75
Table 37:Genetic Testing, France, Company share by Revenue ($m), USD Actual 2009-2010 77
Table 38:Haematology, France, Company share by Revenue ($m), USD Actual 2009-2010 79
Table 39:Histology And Cytology, France, Company share by Revenue ($m), USD Actual 2009-2010 81
Table 40:Immuno Chemistry, France, Company share by Revenue ($m), USD Actual 2009-2010 83
Table 41:Infectious Immunology, France, Company share by Revenue ($m), USD Actual 2009-2010 85
Table 42:Microbiology Culture, France, Company share by Revenue ($m), USD Actual 2009-2010 87
Table 43:In Vitro Diagnostics, Italy, Overall Revenue ($m), USD Actual, 2003-2017 89
Table 44:In Vitro Diagnostics, Italy, Overall Revenue ($m), USD Actual, Historic, 2003-2010 91
Table 45:In Vitro Diagnostics, Italy, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 93
Table 46:Clinical Chemistry, Italy, Distribution Share by Revenue ($m), USD Actual, 2009-2010 94
Table 47:Genetic Testing, Italy, Distribution Share by Revenue ($m), USD Actual, 2009-2010 94
Table 48:Haematology, Italy, Distribution Share by Revenue ($m), USD Actual, 2009-2010 95
Table 49:Histology And Cytology, Italy, Distribution Share by Revenue ($m), USD Actual, 2009-2010 95
Table 50:Immuno Chemistry, Italy, Distribution Share by Revenue ($m), USD Actual, 2009-2010 96
Table 51:Infectious Immunology, Italy, Distribution Share by Revenue ($m), USD Actual, 2009-2010 96
Table 52:Microbiology Culture, Italy, Distribution Share by Revenue ($m), USD Actual, 2009-2010 97
Table 53:In Vitro Diagnostics, Italy, Company share by Revenue ($m), USD Actual, 2009-2010 99
Table 54:Clinical Chemistry, Italy, Company share by Revenue ($m), USD Actual 2009-2010 101
Table 55:Genetic Testing, Italy, Company share by Revenue ($m), USD Actual 2009-2010 103
Table 56:Haematology, Italy, Company share by Revenue ($m), USD Actual 2009-2010 105
Table 57:Histology And Cytology, Italy, Company share by Revenue ($m), USD Actual 2009-2010 107
Table 58:Immuno Chemistry, Italy, Company share by Revenue ($m), USD Actual 2009-2010 109
Table 59:Infectious Immunology, Italy, Company share by Revenue ($m), USD Actual 2009-2010 111
Table 60:Microbiology Culture, Italy, Company share by Revenue ($m), USD Actual 2009-2010 113
Table 61:In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Actual, 2003-2017 115
Table 62:In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Actual, Historic, 2003-2010 117
Table 63:In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 119
Table 64:Clinical Chemistry, United Kingdom, Distribution Share by Revenue ($m), USD Actual, 2009-2010 120
Table 65:Genetic Testing, United Kingdom, Distribution Share by Revenue ($m), USD Actual, 2009-2010 120
Table 66:Haematology, United Kingdom, Distribution Share by Revenue ($m), USD Actual, 2009-2010 121
Table 67:Histology And Cytology, United Kingdom, Distribution Share by Revenue ($m), USD Actual, 2009-2010 121
Table 68:Immuno Chemistry, United Kingdom, Distribution Share by Revenue ($m), USD Actual, 2009-2010 122
Table 69:Infectious Immunology, United Kingdom, Distribution Share by Revenue ($m), USD Actual, 2009-2010 122
Table 70:Microbiology Culture, United Kingdom, Distribution Share by Revenue ($m), USD Actual, 2009-2010 123
Table 71:In Vitro Diagnostics, United Kingdom, Company share by Revenue ($m), USD Actual, 2009-2010 125
Table 72:Clinical Chemistry, United Kingdom, Company share by Revenue ($m), USD Actual 2009-2010 127
Table 73:Genetic Testing, United Kingdom, Company share by Revenue ($m), USD Actual 2009-2010 129
Table 74:Haematology, United Kingdom, Company share by Revenue ($m), USD Actual 2009-2010 131
Table 75:Histology And Cytology, United Kingdom, Company share by Revenue ($m), USD Actual 2009-2010 133
Table 76:Immuno Chemistry, United Kingdom, Company share by Revenue ($m), USD Actual 2009-2010 135
Table 77:Infectious Immunology, United Kingdom, Company share by Revenue ($m), USD Actual 2009-2010 137
Table 78:Microbiology Culture, United Kingdom, Company share by Revenue ($m), USD Actual 2009-2010 139
Table 79:In Vitro Diagnostics, Spain, Overall Revenue ($m), USD Actual, 2003-2017 141
Table 80:In Vitro Diagnostics, Spain, Overall Revenue ($m), USD Actual, Historic, 2003-2010 143
Table 81:In Vitro Diagnostics, Spain, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 145
Table 82:Clinical Chemistry, Spain, Distribution Share by Revenue ($m), USD Actual, 2009-2010 146
Table 83:Genetic Testing, Spain, Distribution Share by Revenue ($m), USD Actual, 2009-2010 146
Table 84:Haematology, Spain, Distribution Share by Revenue ($m), USD Actual, 2009-2010 147
Table 85:Histology and Cytology, Spain, Distribution Share by Revenue ($m), USD Actual, 2009-2010 147
Table 86:Immuno Chemistry, Spain, Distribution Share by Revenue ($m), USD Actual, 2009-2010 148
Table 87:Infectious Immunology, Spain, Distribution Share by Revenue ($m), USD Actual, 2009-2010 148
Table 88:Microbiology Culture, Spain, Distribution Share by Revenue ($m), USD Actual, 2009-2010 149
Table 89:In Vitro Diagnostics, Spain, Company Share by Revenue ($m), USD Actual, 2009-2010 151
Table 90:Clinical Chemistry, Spain, Company Share by Revenue ($m), USD Actual 2009-2010 153
Table 91:Genetic Testing, Spain, Company Share by Revenue ($m), USD Actual 2009-2010 155
Table 92:Haematology, Spain, Company Share by Revenue ($m), USD Actual 2009-2010 157
Table 93:Histology and Cytology, Spain, Company Share by Revenue ($m), USD Actual 2009-2010 159
Table 94:Immuno Chemistry, Spain, Company Share by Revenue ($m), USD Actual 2009-2010 161
Table 95:Infectious Immunology, Spain, Company Share by Revenue ($m), USD Actual 2009-2010 163
Table 96:Microbiology Culture, Spain, Company Share by Revenue ($m), USD Actual 2009-2010 165
Table 97: Clinical Chemisty Market Pipeline Products 179
Table 98: Immuno Chemistry Market Pipeline Products 182
Table 99: Haematology Market Pipeline Products 185
Table 100: Infectious Immunology Market Pipeline Products 187
Table 101: Microbiology Culture Market Pipeline Products 191
Table 102: Histology and Cytology Market Pipeline Products 192
Table 103: Genetic Testing Market Pipeline Products 193
Table 104:Centre For Molecular Medicine And Human Genetics Unit Merge To Form IGMM 198
Table 105:Roche To Acquire Verum Diagnostica For $17.4 Million 199
Table 106:Lepu Medical Technology To Acquire 40% Stake In Comed For $1.9 Million 200
Table 107:Alere Receives Valid Acceptance For Revised Offer To Acquire Axis-Shield For $385 Million 201
Table 108:Grifols Acquires Remaining 51% Stake In Lateral-Medion 203
Table 109:PZ Cormay Acquires 98.62% Stake In Audit Diagnostics 204
Table 110:Roche Completes Acquisition Of mtm laboratories 205
Table 111:bioMerieux Acquires Argene 207
Table 112:Qiagen To Acquire 61% Stake In IPSOGEN 208
Table 113:Lab21 Acquires Myconostica 210
Table 114:Thermo Fisher Completes Acquisition Of Phadia 211
Table 115:bioMerieux Completes Acquisition Of AES Laboratoire 213
Table 116:Ion Beam Applications Acquires 25% Stake In PET Net 215
Table 117:Qiagen Completes Acquisition Of Cellestis 216
Table 118:Techne Acquires Boston Biochem And Boston Biochem 218
Table 119:Merck Acquires heipha Dr. Muller And Related Assets From Biotest 219
Table 120:Agilent Technologies Acquires Lab901 221
Table 121:PerkinElmer Acquires Chemagen Biopolymer 223
Table 122:Imperial Innovations Acquires Minority Stake In Molecular Vision 225
Table 123:AlphaHelix Molecular Diagnostics Acquires Techtum Lab 226
Table 124:ERBA DIAGNOSTICS MANNHEIM Acquires Diasis Diagnostic Systems 227
Table 125:Addtech Life To Acquire Electra-Box Diagnostica 228
Table 126:Lab21 Acquires Microgen Bioproducts 229
Table 127:Global BioDiagnostics Extends Co-Development Agreement With Foundation for Innovative New Diagnostics 230
Table 128:Sony DADC Enters Into Co-Development Agreement With Axela 231
Table 129:Roche Enters Into Joint Venture Agreement With Swiss Federal Institute of Technology, University of Zurich And University Hospital Zurich 232
Table 130:Sony DADC BioSciences Enters Into Co-Development Agreement With Maven Biotechnologies 234
Table 131:Abbott Laboratories Expands Its Co-Development Agreement With GlaxoSmithKline Biologicals 235
Table 132:Dolomite Enters Into Co-Development Agreement With Clearbridge BioMedics 236
Table 133:SuperNova Diagnostics Enters Into Co-Development Agreement With Concile 237
Table 134:Dako Enters Into Co-Development Agreement With Bristol-Myers 238
Table 135:Transgenomic Enters Into Distribution Agreement With ScreenCell 239
Table 136:Oxford Gene Technology Enters Into Co-Development Agreement With Abcodia 240
Table 137:Horizon Discovery Enters Into Co-Development Agreement With Promega 241
Table 138:Sony DADC Enters Into Co-Development Agreement With Anagnostics Bioanalysis 242
Table 139:Life Technologies Enters Into Co-Development Agreement With GlaxoSmithKline Biologicals 243
Table 140:Axis-Shield Enters Into Co-Development Agreement With Siemens Healthcare Diagnostics 244
Table 141:TcLand Expression Enters Into Co-Development Agreement With Radboud University Nijmegen 245
Table 142:Generation Scotland Enters Into Co-Development Agreement With Arrayjet 246
Table 143:Accelr8 Technology Amends Licensing Agreement With SCHOTT 247
Table 144:Orion Genomics Enters Into Licensing Agreement With QIAGEN 248
Table 145:Almac Group Enters Into Research Agreement With Queen’s University Belfast 249
Table 146:QIAGEN Enters Into Co-Development Agreement With Eli Lilly 250
Table 147:Skyline Diagnostics Enters Into Research Agreement With Clavis Pharma 251
Table 148:Lumora Enters Into Licensing Agreement With 3M 252
Table 149:Quanterix Enters Into Co-Development Agreement With STRATEC Biomedical 253
Table 150:Sequenom Enters Into Licensing Agreement With LifeCodexx 254
Table 151:Enigma Diagnostics Enters Into Co-Development Agreement With GlaxoSmithKline 255
Table 152:BD Diagnostics Enters Into Co-Development Agreement With Lab21 256
Table 153:Hycor Biomedical Signs Licensing Agreement With Eurospital 257
Table 154:Hycor Biomedical Signs Licensing Agreement With Axis-Shield 258
Table 155:Quanterix Enters Into Co-Development Agreement With Sony DADC 259
Table 156:Mayo Medical Laboratories Enters Into Licensing Agreement With Qiagen 260
Table 157:Proteome Sciences Enters Into Collaboration With Buck Institute 261
Table 158:Proteome Sciences Enters Into Co-Development Agreement With H. Lee Moffitt Cancer Center 262
Table 159:Skyline Diagnostics Enters Into Research Collaboration With Johnson & Johnson Pharmaceutical 263
Table 160:Metamark Genetics Enters Into Co-Development Agreement With Definiens 264
Table 161:Bruker Daltonics Enters Into Distribution Agreement With Francisco Soria Melguizo 265
Table 162:Roche Enters Into Collaboration With Evotec 266
Table 163:Life Technologies, Oxford Biomedical Research Centre, AstraZeneca And ORD Enter Into Co-Development Agreement 267
Table 164:ResearchDx Enters Into Partnership With CompanDX 268
Table 165:Source BioScience Enters Into Co-Development Agreement With Barts Cancer Institute And Illumina 269
Table 166:University of Geneva, Hopitaux Universitaires de Geneve, SIB And Roche Form Partnership 270
Table 167:F. Hoffmann-La Roche Enters Into Co-Development Agreement With Merck 271
Table 168:Roche Enters Into Co-Development Agreement With Clovis Oncology 272
Table 169:Roche Applied Science Enters Into Partnership With TIB MOLBIOL 273
Table 170:Pacific Edge Biotechnology Enters Into Licensing Agreement With Oryzon Genomics 274
Table 171:EKF Diagnostics Enters Into Distribution Agreement With Alere 275
Table 172:AbD Serotec Enters Into Licensing Agreement With Proteomika 276
Table 173:BD Diagnostic Enters Into Co-Development Agreement With Diagenode 277
Table 174:Atonomics Enters Into An Agreement With Beckman Coulter 278
Table 175:Royal Philips Electronics Enters Into Co-Development Agreement With NEC 279
Table 176:Precision System Science Enters Into Co-Development Agreement With Biotrin International 280
Table 177:Genmab Enters Into Research Collaboration With Seattle Genetics 281
Table 178:Biofortuna Enters Into Distribution Agreement With Abbott 282
Table 179:Advanced Cell Diagnostics Enters Into Co-Development Agreement With Definiens 283
Table 180:DNA Genotek Enters Into Distribution Agreement With Abyntek Biopharma 284
Table 181:BioFocus Enters Into An Agreement With Almac Group 285
Table 182:Seegene Enters Into An Agreement With Molzym 286
Table 183:Dako Denmark Enters Into Co-Development Agreement With Epitomics 287
Table 184:Accelrys Enters Into Co-Development Agreement With Oxford Nanopore 288
Table 185:Ascent Scientific Enters Into Licensing Agreement With Children’s Memorial Hospital And The University Of Newcastle 289
Table 186:Genomic Expression Enters Into An Agreement With Copenhagen University, Beijing Genome Institute And Bavarian Nordic 290
Table 187:BioPorto Enters Into Licensing Agreement With Instrumentation Laboratory 291
Table 188:Oxford Medical Diagnostics Enters Into Co-Marketing Agreement With V&F Analyse 292
Table 189:FIND Enters Into An Agreement With Global BioDiagnostics 293
Table 190:Epigenomics Enters Into Research Licensing Agreement With QIAGEN 294
Table 191:CompanDX Enters Into Agreement With Clinical Reference Laboratory 295
Table 192:Trinity Biotech Enters Into Distribution Agreement With A. Menarini Diagnostics 296
Table 193:PROGEN Biotechnik Enters Into Distribution Agreement With Mitsubishi Chemical 297
Table 194:NorDiag Enters Into Agreement With Precision System Science 298
Table 195:Consort Medical Enters Into Co-Development Agreement With Atlas Genetics 299
Table 196:Cepheid Enters Into Co-Development Agreement With FIND 300
Table 197: USD to Local Currency, Europe, Average Exchange Rate 2003-2010 380
List of Figures
Figure 1:In Vitro Diagnostics, Cross Country Comparison, USD Actual, 2003-2017 25
Figure 2:In Vitro Diagnostics, Europe, Overall Revenue ($m), USD Actual, 2003-2017 26
Figure 3:In Vitro Diagnostics, Europe, Cross-Category Analysis, 2003-2017 28
Figure 4:In Vitro Diagnostics, Europe, Overall Revenue ($m), USD Actual, Historic, 2003-2010 30
Figure 5:In Vitro Diagnostics, Europe, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 32
Figure 6:In Vitro Diagnostics, Europe, Company share (%), 2010 34
Figure 7:In Vitro Diagnostics, Germany, Overall Revenue ($m), USD Actual, 2003-2017 36
Figure 8:In Vitro Diagnostics, Germany, Overall Revenue ($m), USD Actual, Historic, 2003-2010 38
Figure 9:In Vitro Diagnostics, Germany, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 40
Figure 10:In Vitro Diagnostics, Germany, Company Share (%), 2010 46
Figure 11:Clinical Chemistry, Germany, Company Share (%), 2010 48
Figure 12:Genetic Testing, Germany, Company Share (%), 2010 50
Figure 13:Haematology, Germany, Company Share (%), 2010 52
Figure 14:Histology And Cytology, Germany, Company Share (%), 2010 54
Figure 15:Immuno Chemistry, Germany, Company Share (%), 2010 56
Figure 16:Infectious Immunology, Germany, Company Share (%), 2010 58
Figure 17:Microbiology Culture, Germany, Company Share (%), 2010 60
Figure 18:In Vitro Diagnostics, France, Overall Revenue ($m), USD Actual, 2003-2017 62
Figure 19:In Vitro Diagnostics, France, Overall Revenue ($m), USD Actual, Historic, 2003-2010 64
Figure 20:In Vitro Diagnostics, France, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 66
Figure 21:In Vitro Diagnostics, France, Company Share (%), 2010 72
Figure 22:Clinical Chemistry, France, Company share (%), 2010 74
Figure 23:Genetic Testing, France, Company share (%), 2010 76
Figure 24:Haematology, France, Company share (%), 2010 78
Figure 25:Histology And Cytology, France, Company share (%), 2010 80
Figure 26:Immuno Chemistry, France, Company share (%), 2010 82
Figure 27:Infectious Immunology, France, Company share (%), 2010 84
Figure 28:Microbiology Culture, France, Company share (%), 2010 86
Figure 29:In Vitro Diagnostics, Italy, Overall Revenue ($m), USD Actual, 2003-2017 88
Figure 30:In Vitro Diagnostics, Italy, Overall Revenue ($m), USD Actual, Historic, 2003-2010 90
Figure 31:In Vitro Diagnostics, Italy, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 92
Figure 32:In Vitro Diagnostics, Italy, Company share (%), 2010 98
Figure 33:Clinical Chemistry, Italy, Company share (%), 2010 100
Figure 34:Genetic Testing, Italy, Company share (%), 2010 102
Figure 35:Haematology, Italy, Company share (%), 2010 104
Figure 36:Histology And Cytology, Italy, Company share (%), 2010 106
Figure 37:Immuno Chemistry, Italy, Company Share (%), 2010 108
Figure 38:Infectious Immunology, Italy, Company share (%), 2010 110
Figure 39:Microbiology Culture, Italy, Company share (%), 2010 112
Figure 40:In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Actual, 2003-2017 114
Figure 41:In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Actual, Historic, 2003-2010 116
Figure 42:In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 118
Figure 43:In Vitro Diagnostics, United Kingdom, Company share (%), 2010 124
Figure 44:Clinical Chemistry, United Kingdom, Company share (%), 2010 126
Figure 45:Genetic Testing, United Kingdom, Company share (%), 2010 128
Figure 46:Haematology, United Kingdom, Company share (%), 2010 130
Figure 47:Histology And Cytology, United Kingdom, Company share (%), 2010 132
Figure 48:Immuno Chemistry, United Kingdom, Company share (%), 2010 134
Figure 49:Infectious Immunology, United Kingdom, Company share (%), 2010 136
Figure 50:Microbiology Culture, United Kingdom, Company share (%), 2010 138
Figure 51:In Vitro Diagnostics, Spain, Overall Revenue ($m), USD Actual, 2003-2017 140
Figure 52:In Vitro Diagnostics, Spain, Overall Revenue ($m), USD Actual, Historic, 2003-2010 142
Figure 53:In Vitro Diagnostics, Spain, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 144
Figure 54:In Vitro Diagnostics, Spain, Company Share (%), 2010 150
Figure 55:Clinical Chemistry, Spain, Company Share (%), 2010 152
Figure 56:Genetic Testing, Spain, Company Share (%), 2010 154
Figure 57:Haematology, Spain, Company Share (%), 2010 156
Figure 58:Histology and Cytology, Spain, Company Share (%), 2010 158
Figure 59:Immuno Chemistry, Spain, Company Share (%), 2010 160
Figure 60:Infectious Immunology, Spain, Company Share (%), 2010 162
Figure 61:Microbiology Culture, Spain, Company Share (%), 2010 164
Figure 62:F. Hoffmann-La Roche Ltd., Company Share (%), Europe In Vitro Diagnostics Market, 2010 166
Figure 63:Siemens Healthcare, Company Share (%), Europe In Vitro Diagnostics Market, 2010 167
Figure 64:Abbott Laboratories, Company Share (%), Europe In Vitro Diagnostics Market, 2010 168
Figure 65:Beckman Coulter, Inc., Company Share (%), Europe In Vitro Diagnostics Market, 2010 169
Figure 66:bioMerieux S.A., Company Share (%), Europe In Vitro Diagnostics Market, 2010 170
Figure 67:Ortho-Clinical Diagnostics Inc., Company Share (%), Europe In Vitro Diagnostics Market, 2010 171
